Sastasundar Ventures Ltd (HEALTHX) Q3FY26 Concall Summary - Dec-2025 Qtr
Performance Overview
- The company demonstrated a strong operational quarter, marking a return to growth after a period of steady revenue, driven by automation and improved operational efficiencies across both B2B and B2C verticals.
- Revenue grew significantly by 22% YoY and 11% QoQ, indicating a robust recovery and sustained traction in core business segments.
- Profitability metrics showed meaningful improvement, with gross margins expanding to 7.6% and a sharp turnaround at the operating level, moving from a significant loss to a positive EBIT.
- The company remains highly capital-efficient, funding its technology-focused growth initiatives primarily through treasury income, thereby maintaining a positive cash flow.
- Strategic initiatives are progressing well, with the B2B segment, Retailer Shakti, on track for EBITDA break-even by Q4 FY26, and the B2C segment, SastaSundar, aiming for contribution margin positivity in FY27.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.